Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …

Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) T cells holds impressive
clinical outcomes especially in patients who are refractory to other kinds of therapy …

In currently ongoing adoptive T-cell therapies, T cells collected from the patient are given
back to the patient after ex vivo cell activation and expansion. In some cases, T cells are …

Progress in adoptive T-cell therapy for cancer and infectious diseases, is hampered by the
lack of readily available, antigen-specific, human T lymphocytes. Pluripotent stem cells could …

Adoptive therapeutic immune cells, such as chimeric antigen receptor (CAR)-T cells and
natural killer cells, have established a new generation of precision medicine based on which …

The effectiveness of chimaeric antigen receptor (CAR) T-cell immunotherapies against solid
tumours relies on the accumulation, proliferation and persistency of T cells at the tumour site …

Simple Summary Induced pluripotent stem cells (iPSCs) that can be genetically engineered
and differentiated into different types of immune cells, providing an unlimited resource for …

Technologies required to generate induced pluripotent stem cells (iPSC) were first
described 15 years ago, providing a strong impetus to the field of regenerative medicine. In …

The development of induced pluripotent stem cell (iPSC) technology has generated
enthusiasm about the therapeutic potential of these cells for treating a variety of diseases …

Human induced pluripotent stem cells (iPSCs) are a potential source of blood cells for
transfusion therapies and a promising tool for studying the ontogeny of hematopoiesis. The …